| 52.1 -0.09 (-0.17%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 64.2  |
1-year : | 67.12 |
| Resists | First : | 54.96 |
Second : | 57.47 |
| Pivot price | 53 |
|||
| Supports | First : | 50.91 | Second : | 42.36 |
| MAs | MA(5) : | 51.92  |
MA(20) : | 53.3 |
| MA(100) : | 51.42 |
MA(250) : | 43.6 |
|
| MACD | MACD : | -1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 20.5 |
D(3) : | 20.9 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 63.95 | Low : | 30 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ XENE ] has closed above bottom band by 30.0%. Bollinger Bands are 40.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 53.16 - 53.43 | 53.43 - 53.64 |
| Low: | 51.28 - 51.64 | 51.64 - 51.93 |
| Close: | 51.6 - 52.14 | 52.14 - 52.58 |
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Mon, 08 Jun 2026
Xenon Pharmaceuticals (XENE) director Cannon sells 1,190 shares under 10b5-1 tax plan - Stock Titan
Mon, 08 Jun 2026
Xenon (XENE) director Patou sells 1,322 shares in tax-related 10b5-1 trade - Stock Titan
Fri, 05 Jun 2026
[144] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
Wed, 03 Jun 2026
Xenon Pharmaceuticals (XENE) director awarded RSUs, options and exercises vested RSUs - Stock Titan
Tue, 02 Jun 2026
Xenon Pharmaceuticals Inc. Rings the Opening Bell - Nasdaq
Fri, 29 May 2026
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 107.2 (%) |
| Shares Short | 3,830 (K) |
| Shares Short P.Month | 4,850 (K) |
| EPS | -4.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24.3 % |
| Return on Equity (ttm) | -37.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.4 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -306 (M) |
| Levered Free Cash Flow | -186 (M) |
| PE Ratio | -11.09 |
| PEG Ratio | 0 |
| Price to Book value | 7.16 |
| Price to Sales | 0 |
| Price to Cash Flow | -16.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|